Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in…
Turning Point Therapeutics, Inc. and Zai Lab announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in…
Read More...
Read More...
